Introduction {#S1}
============

Lung cancer (LUCA) is an aggressive disease with leading mortality and incidence in the world. Based on histology, there are two types of LUCA, including non-small cell lung cancer (NSCLC), which accounts for 80% of LUCA and small cell lung cancer (SCLC), which accounts for approximately 20% of LUCA ([@B34]; [@B7]). NSCLC can be further sub-divided into four subtypes, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and bronchioloalveolar carcinoma ([@B33]). Classical histological subtypes indeed play a dominant role in treatment and prognosis of lung cancer. Recently, reclassification of lung cancer based on tumor biomarkers improves lung cancer therapy ([@B3]; [@B17]).

Many studies have demonstrated that using clinical-association-prognostic biomarkers can assist the characterization of cancer subtypes and provide new insights of cancer recurrence and patients response to more precise therapies ([@B29]; [@B4]; [@B34]). It is worth noting that numerous single- or multi-prognostic biomarkers have been identified using high-throughput profiling methods ([@B34]). By mining a mass of these profiling data deposited in public database, meta-analysis has exploited potential prognostic genes, such as *KRT8* ([@B54]). However, for biologists and clinicians, it is technically difficult to analyze these massive public data to screen and develop prognostic biomarkers. Previously, we have built several web servers of prognostic biomarker analysis for breast cancer, esophageal carcinoma, etc. ([@B48],[@B50],[@B51], [@B49]; [@B55],[@B56]; [@B58]; [@B60], [@B59]; [@B10]). In this current study, we have integrated bulky RNA expression profiles of lung cancer with clinical survival information, mainly from TCGA (The Cancer Genome Atlas) and GEO (the Gene Expression Omnibus) databases, and built a prognostic analysis web server named OSluca (Online consensus Survival for Lung Cancer) to analyze and evaluate prognostic potency of gene in 35 independent lung cancer cohorts.

Materials and Methods {#S2}
=====================

Collection of Lung Cancer Datasets {#S2.SS1}
----------------------------------

The lung cancer cohorts for OSluca with expression profiling and clinical follow-up data were collected from PubMed, TCGA,^[1](#footnote1){ref-type="fn"}^ and GEO^[2](#footnote2){ref-type="fn"}^ by searching the keywords: "lung" AND "cancer" AND "survival" ([Table 1](#T1){ref-type="table"}). The dataset for each cohort that met these following criteria will be included in OSluca: (1) have RNA sequencing or gene microarray data; (2) have complete follow-up data, such as overall survival and status ([@B26]); (3) all the data were specific for lung cancer, not from secondary or metastatic lung tumor from other types of tumors; (4) the cohort size is no less than 30 cases. The primary clinical pathological characteristics of lung cancer patients are listed in [Table 1](#T1){ref-type="table"}.

###### 

Summary of clinical characteristics of lung cancer cohorts in Online Consensus Survival for Lung Cancer (OSluca).

                             **NSCLC**               **SCLC (*N* = 223)**   **\#NA (*N* = 85)**                                                    
  -------------------------- ----------------------- ---------------------- --------------------- ---------------- --------------- --------------- ---------------
  Age, year                  64 (13--91)             64 (13--90)            66 (39--83)           63 (39--81)      62 (22--80)     64 (40--83)     58 (15--82)
  Gender                                                                                                                                           
  Male, %                    52.6                    46.9                   68.3                  77.2             12.9            58.1            50
  Female, %                  38.8                    47.7                   23.7                  18.1             12.4            41.9            50
  \#NA, %                    8.6                     5.4                    8.0                   4.7              73.7            0               0
  Stage\*                                                                                                                                          
  I, *n*                     2301                    1,653                  567                   66               28              10              9
  II, *n*                    889                     500                    347                   27               15              5               4
  III, *n*                   595                     366                    199                   18               12              2               3
  IV, *n*                    101                     73                     13                    2                13              0               0
  T stage 1/2/3/4/\#NA       646/1074/230/103/2884   468/663/102/49/2063    155/362/109/39/716    20/44/17/9/107   3/5/2/6/178     11/13/5/4/190   28/20/10/6/21
  N Stage 0/1/2/3/\#NA       1638/495/280/21         1038/254/198/5/1859    549/218/70/7/537      48/20/17/5/107   3/3/4/4/180     14/4/12/6/187   33/25/5/1/21
  M stage 0/1/\#NA           1685/42/3210            853/26/2466            740/8/633             82/2/113         10/6/178        33/4/186        63/2/20
  Smoking/non-smoking/\#NA   1839/262/2836           1112/256/1977          618/3/760             40/1/156         9/2/183         18/1/204        9/8/68
  OS, mo                     46 (0.03--256)          48 (0.03--242)         41 (0.03--256)        46 (0.1--216)    38 (0.5--208)   51 (2--211)     68 (2--244)
  DSS, mo                    42 (0.03--256)          43 (0.19--242)         41 (0.03--256)        45 (1--216)      36 (6--76)      24 (2--140)     69 (2--244)
  DFI, mo                    33 (0.16--242)          32 (0.6--242)          34 (0.16--159)        --               --              --              --
  PFI, mo                    33 (0.03--242)          36 (0.03--242)         30 (0.03--180)        53 (1.8--164)    4 (0.23--54)    --              30 (2--73)

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell cancer; NOS, NSCLC, not otherwise specified; F, female; M, male; n, number; mo, months; OS, overall survival; DSS, disease-specific survival; DFI, disease-free interval; PFI, progression-free interval or recurrence free survival. \*The stage only counts stages of lung cancer patients described in the original datasets; \#NA, data lost or unknown.

Construction of OSluca Web Server {#S2.SS2}
---------------------------------

Online consensus Survival for Lung Cancer is built in a tomcat server as previously described with minor modifications ([@B50], [@B51]; [@B55], [@B56]; [@B58]; [@B60]). Briefly, front-end application was used for inputting query and displaying the results. Java and R package were used to analyze request and output the results. In addition, profiles and clinical information were stored in the SQL Server database. The prognostic significance of inputted gene is determined by analyzing the association of gene expression and survival time using the R package "survival." In addition, a genome-wide pre-calculation of Cox proportional regression for all the human genes were performed as well, and the home page of OSluca could display the survival analysis summary with a forest plot and a table of Cox proportional regression result for inputted gene in all cohorts with *P*-value and HR \[(95% confidence interval (CI)\] with the built-in upper 25% cutoff. The R package "forestplot" was used to produce the forest plot for inputted gene in OSluca web server.

Validation of Previously Reported Prognostic Biomarkers of Lung Cancer in OSluca {#S2.SS3}
--------------------------------------------------------------------------------

Keywords including "lung cancer," "survival," "biomarker," and "prognosis" were used to search biomarkers of lung cancer in NCBI PubMed. We finally obtained 104 prognostic biomarkers using the following criteria ([Table 2](#T2){ref-type="table"}): (1) immunohistochemistry (IHC) or qRT-PCR (qPCR) detection of biomarkers in primary cancer tissue; (2) a significant association between biomarker and survival; (3) the sample size must be above 50 cases; (4) the study was published in the English for full access.

###### 

Clinico-pathological traits of lung cancer cohorts.

  **Datasets**    **Cohorts**   **Platform**   **Histological type**   **Survival**     **Samples**       **References**
  --------------- ------------- -------------- ----------------------- ---------------- ----------------- ------------------------
  Rockville       GSE102287     GPL570         AD/SCC/NOS              OS               32                [@B30]
  Heidelberg      GSE10245      GPL570         AD/SCC                  OS               58                [@B21]
  Koto-ku         GSE1037       GPL962         AD/SCC/SCLC             OS               61                [@B20]
  Basel           GSE11117      GPL6650        AD/SCC/NOS              OS               41                [@B2]
  Nagoya          GSE11969      GPL7015        AD/SCC/LCC              OS               149               [@B42]
  Groningen       GSE12428      GPL1708        SCC                     OS               34                [@B5]
  Nagoya          GSE13213      GPL6480        AD                      OS               117               [@B47]
  Toronto         GSE14814      GPL96          AD/SCC/NOS              OS/DSS           133               [@B62]
  Chapel Hill     GSE17710      GPL9053        SCC                     OS/PFI           56                [@B52]
  Rotterdam       GSE19188      GPL570         AD/SCC/LCC              OS               82                [@B18]
  Chapel Hill     GSE26939      GPL9053        AD                      OS               116               [@B53]
  Dallas          GSE29013      GPL570         AD/SCC                  OS/PFI           55                [@B57]
  Lund            GSE29066      GPL6947        AD/SCC/SCLC             OS               68                [@B41], [@B40]
  La Tronche      GSE30219      GPL570         AD/SCC/SCLC/LCC         OS/DFS           293               [@B37]
  Chuo-ku         GSE31210      GPL570         AD                      OS/PFI           226               [@B32]
  Durham          GSE3141       GPL570         AD/SCC                  OS               111               [@B4]
  Dallas          GSE31908      GPL96/97       AD                      OS               30                NA
  Houston         GSE33072      GPL6244        AD/SCC                  PFI              66                [@B8]
  Uppsala         GSE37745      GPL570         AD/SCC/LCC              PFI              196               [@B6]
  Dallas          GSE41271      GPL6884        AD/SCC/LCC              OS/PFI           275               [@B38]
  San Diego       GSE4573       GPL96          SCC                     OS               130               [@B34]
  Nagoya          GSE4716       GPL3696/3694   AD/SCC/LCC              OS               50                [@B46]
  Toronto         GSE50081      GPL570         AD/SCC/LCC              OS/DFS           181               [@B9]
  Brisbane        GSE5123       GPL3877        SCC                     OS               51                [@B23]
  Brisbane        GSE5828       GPL3877        SCC                     OS               59                [@B22]
  Brisbane        GSE5843       GPL3877        AD                      OS               48                [@B24]
  St. Louis       GSE6253       GPL8300        AD/SCC/NOS              DSS              34                [@B27]
  Bethesda        GSE63459      GPL6883        AD                      OS               33                [@B35]
  Stanford        GSE67639      GPL570         AD/SCC/NOS              OS               1106              [@B13]
  Rockville       GSE68465      GPL96          AD                      OS/PFI           442/363           [@B39]
  Rockville       GSE68571      GPL80          AD                      OS               86                [@B3]
  Seoul           GSE8894       GPL570         AD/SCC                  PFI              138               [@B25]
  NIH and NHGRI   TCGA          DCC            AD                      OS/DSS/DFI/PFI   513/478/306/513   [@B45]; [@B26]
  NIH and NHGRI   TCGA          DCC            SCC                     OS/DSS/DFI/PFI   498/452/303/499   [@B16]; [@B44]; [@B26]
  Reopman         Roepman                      AD/SCC/LCC/NOS          OS               172               [@B36]

NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; AD, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma; NOS, not otherwise specified; OS, overall survival; DSS, disease-specific survival; DFI, disease-free interval; PFI, progression-free interval.

Statistical Analysis {#S2.SS4}
--------------------

The association of lung cancer clinical factors and survival outcomes was analyzed by GraphPad Prism 8.0 software. The Cox proportional hazards regression and Kaplan Meier plot functions from R package "survival" were used in the OSluca to determine the association between gene expression and survival. The *P* ≤ 0.05 was considered statistically significant.

Results {#S3}
=======

Clinical Characteristics of Lung Cancer Patients in OSluca {#S3.SS1}
----------------------------------------------------------

To develop an online survival web server for lung cancer, we collected 35 published high-throughput profiling datasets of lung cancer with long-term follow-up information (2 TCGA datasets, 32 GEO datasets, and 1 Roepman dataset). TCGA comprises 513 lung adenocarcinoma cases and 499 squamous cell carcinoma cases ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). GEO cohorts and Roepman cohort had more than 4,000 samples and 172 samples, respectively, as shown in [Table 2](#T2){ref-type="table"}. 4,901 patients have OS (overall survival) data; 2,176 patients have DSS (disease-specific survival) data; and 2,075 patients have PFI (progression-free interval or recurrence-free survival) data, while 608 patients have DFI (disease-free interval) data. The results showed that the patients with lung adenocarcinoma significantly survive longer than those of other histological lung cancer, and small cell lung cancer is associated with the worst prognosis compared to other types of lung cancer ([Figure 1A](#F1){ref-type="fig"}). Moreover, other clinical characteristics can also prominently affect patients' prognosis, such as gender (*P* \< 0.0001), stage (*P* \< 0.0001), p-TNM stage (*P* \< 0.0001), and smoking status (*P* \< 0.0001) ([Figures 1B--E](#F1){ref-type="fig"}). Besides, these risk factors can influence other survival endpoints, such as PFI (data not shown). These results are in accordance with previous researches ([@B28]; [@B7]).

![Correlation between the clinico-pathologic characteristics and overall survival of lung cancer in Online Consensus Survival for Lung Cancer (OSluca). **(A)** Correlation between histological types and OS. **(B)** Correlation between gender and OS. **(C)** Correlation between tumor stages and OS. **(D)** Correlation between p-TNM stages and OS. **(E)** Correlation between smoking status and OS. OS, overall survival; AD, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell cancer.](fgene-11-00420-g001){#F1}

Construction and Usage of Prognostic Web Server OSluca {#S3.SS2}
------------------------------------------------------

Online consensus Survival for Lung Cancer includes a set of optional clinico-pathological factors, such as age, sex, histological type, grade, smoking status, and so on. Four survival endpoints can be selected basing on original patient outcomes, containing OS, DSS, DFI, and PFI ([@B26]). In order to make the user clearly see the prognostic effect of interested gene, a meta-analysis is to summarize the prognostic value for each gene on the home page of OSluca. Briefly, after the user types the official gene symbol into the input box on the home page, OSluca will display the survival analysis summary with a forest plot and a table from Cox proportional regression in each cohort and combined cohorts (combining all the datasets together). Take the tumor suppressor gene *TP53* (tumor protein p53) as an example and type "TP53" into the gene symbol box and click on "Survival analysis" ([Figure 2A](#F1){ref-type="fig"}, left). The meta-analysis results with a forest plot and a survival table for the *TP53* gene, will display the *P*-value and HR with 95% CI of each cohort and the combined cohorts ([Figure 2A](#F2){ref-type="fig"}, right). Then, the user can easily obtain KM plots of separate cohorts such as GSE30219 dataset by clicking on the "Go" button in the survival table ([Figure 2B](#F2){ref-type="fig"}). In addition, it is also available to use a subgroup of certain cohort to obtain specific prognostic information with selectable risk factors, such as cutoff value, histological type, grade, etc. Briefly, OSluca can output survival rates displaying a forest plot and a survival table with KM plot and *P*-value to measure the association between the investigated gene and survival rate.

![The output home page and KM output web subpage in OSluca for lung cancer. **(A)** Home page of OSluca with *TP53* gene survival analysis, containing prognostic meta-analysis of a forest plot and a survival table. **(B)** KM plots of *TP53* gene in the GSE30219 cohort. Note: the cutoff value is the upper 25% vs. other 75%. The "Combined" in forest plot and survival table means the overall prognostic significance of inputted gene in a pooling cohort with all the datasets. TP53, tumor protein p53.](fgene-11-00420-g002){#F2}

Validation of Previously Reported Lung Cancer Prognostic Biomarkers in OSluca {#S3.SS3}
-----------------------------------------------------------------------------

A search for lung cancer biomarkers was performed using a set of keywords in NCBI PubMed, including "lung cancer," "survival," "biomarker," and "prognosis." In total, we collected 104 published lung cancer prognostic biomarkers verified by IHC or qPCR ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}) to evaluate the performance of OSluca. For example, Hsu et al. reported that *ERO1L* (ERO1-like protein alpha, also named *ERO1A*) is significantly overexpressed in tumor tissue and could be as a poor prognostic biomarker for lung adenocarcinoma ([@B19]). The prognostic analysis of *ERO1L* in OSluca showed that high expression of *ERO1L* gene is significantly associated with poor outcome in eight out of nine cohorts (Top 9 cohorts, the sample size above 150 cases) ([Figures 3A--H](#F3){ref-type="fig"}), except the Roepman dataset ([Figure 3I](#F3){ref-type="fig"}). Next, each published biomarker was investigated in the Top 9 cohorts in OSluca, and the results showed that approximately 66% of biomarkers (69/104) were consistent with original published findings ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). Meanwhile, OSluca can be used to perform the outcome meta-analysis of the interested gene that showed that 14% (14/104) ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}) of published prognostic genes have the similar prognostic values in one or multiple OSluca cohorts as reported in the literature, but these genes also showed the opposite outcomes in some other cohorts from OSluca. These genes need further investigations, such as the *DDIT3* gene ([Supplementary Figure S2](#FS1){ref-type="supplementary-material"} and [Supplementary Table S1](#TS1){ref-type="supplementary-material"}). In contrast, there are some prognostic biomarkers, which have been shown different outcomes between OSluca and previous findings. A total of 9% of the published prognostic genes showed opposite outcome results between OSluca and literatures (9/104) (see [Supplementary Table S1](#TS1){ref-type="supplementary-material"}), suggesting that these genes need further validation. For example, the transcription factor *KLF15* (Krüppel-like factor 15) had been proven to be higher in tumor tissue than that of adjacent non-tumor tissue and played an important role in promoting proliferation and carcinoma diversification in lung adenocarcinoma, associated with poor prognostic outcome ([@B12]). It was not anticipated that the patients with high expression of *KLF15* have better survival than those with low expression ([Supplementary Table S1](#TS1){ref-type="supplementary-material"} and [Supplementary Figure S1](#FS1){ref-type="supplementary-material"}). The OSluca result for the *KLF15* gene was consistent with other prognostic analysis tools ([@B15]; [@B1]), such as the KM plotter \[*P* \< 0.001, HR (95% CI) = 0.4 (0.28--0.58)\]. In addition, the remaining 12 of 104 previously published prognostic biomarkers (11%) were not significant for prognostic analysis in the Top 9 cohorts in OSluca, but 8 of them (8/12) are significant in one or multiple datasets other than the Top 9 cohorts in OSluca (data not shown). All in all, the OSluca server is an interactive and free web server for researchers to develop potential prognostic biomarkers for lung cancer.

![Validation of a previously reported biomarker *ERO1L* in OSluca. Overexpression of *ERO1L* in tumor tissue is suggested as a worse survival biomarker in lung adenocarcinoma. **(A)** Overall survival (OS) of *ERO1L* gene in GSE30219 cohort. **(B)** OS in GSE31210 cohort. **(C)** OS in GSE37745 cohort. **(D)** OS in GSE41271 cohort. **(E)** OS in GSE50081 cohort. **(F)** OS in GSE67639 cohort. **(G)** OS in GSE68465 cohort. **(H)** OS in TCGA in lung adenocarcinoma. **(I)** OS in Roepman cohort. The histological type of all the above cohorts is lung adenocarcinoma. ERO1L, ERO1-like protein alpha (also named ERO1A).](fgene-11-00420-g003){#F3}

Discussion {#S4}
==========

Owing to tumor molecular heterogeneity, the prognosis of lung cancer patients is variable and difficult to predict. The prognosis of patients suffering from lung cancer had been demonstrated to be highly dependent on clinical factors of the patient, such as histological type, smoking status, and so on. However, it is also an imperative need to exploit novel prognostic biomarkers for determining the risk of cancerous lesions and predicting lung cancer patient outcomes by all available means, especially by high-throughput sequencing technologies. However, one major challenge to non-bioinformatics researchers is how to integrate the high-dimension profiling datasets of lung cancer and discover new biomarkers to potentially guide prognostic stratification. Previous studies had revealed that the online prognostic web servers of cancer ([@B11]; [@B31]; [@B14]; [@B15]; [@B43]) could substantially help researchers to discover potential biomarkers ([@B61]). Herein, we developed a free web server OSluca to assess the prognostic value of the interesting gene in multiple cohorts of lung cancers. In OSluca, all the lung cancer cases are originated from the organ lung, not the second cancer from other cancers or organs. As a result, the prognostic specificity is only for lung cancer. Nevertheless, its prognostic significance in other types of cancers is also worth to be determined. To access the repeatability of previously reported prognostic biomarkers in OSluca, we collected 104 previously published prognostic biomarkers of lung cancer identified by qPCR or IHC, and tested their prognostic significance in OSluca. The testing results showed that most of the biomarkers were verified in OSluca and were confirmed for the published findings. Nevertheless, some genes showed different prognostic outcomes compared to previous literatures.

The advantage of OSluca over other online prognostic web servers is that the size of lung cancer samples in OSluca is large, and tens of independent cohorts are available, which is extremely valuable for the identification and validation of cancer prognostic biomarkers, since the most important part for the biomarker development is independent validation across different datasets/cohorts. The limitation of the current study is that OSluca can only test a single gene for outcome analysis. In summary, OSluca is a free web server for non-bioinformatics researchers to study potential lung cancer prognostic biomarkers, accessed at <http://bioinfo.henu.edu.cn/LUCA/LUCAList.jsp>.
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